Achlorhydria

Summary

Achlorhydria (MONDO:0043465) is a disease and 6 clinical trials. Top therapeutic interventions include esomeprazole and omeprazole. A subtype of stomach disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	achlorhydria
Mondo ID	MONDO:0043465
MeSH	D000126
ICD-10-CM	K31.83
ICD-11	157689543
NCIT	C2850
SNOMED CT	47481007
UMLS	C0001075
MedGen	1714
Is cancer (heuristic)	no

Also known as: achlorhydria · achylia gastrica · hypochlorhydria

Disease family

This is a subtype of stomach disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › stomach disorder › achlorhydria

Related subtypes (18): gastric ulcer, functional gastric disease, Dieulafoy lesion, pylorospasm, cascade stomach, pyloric stenosis, gastric dilatation, stomach diverticulosis, gastritis, gastroesophageal reflux disease, hiatus hernia, stomach polyp, non-hypoproteinemic hypertrophic gastropathy, gastric neoplasm, angiodysplasia of stomach, gastric intestinal metaplasia, gastric duplication, pyloric duplication

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE1	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00582972	PHASE4	COMPLETED	Does Omeprazole Decrease Intestinal Calcium Absorption?
NCT04199624	PHASE1	COMPLETED	Assessment of Gastric pH Changes Induced by Ascorbic Acid Tablets
NCT04942652	PHASE1	COMPLETED	Study to Evaluate Effects of Food or Proton Pump Inhibitor on the Pharmacokinetics of Itraconazole in Healthy Volunteers
NCT00001240	Not specified	COMPLETED	Evaluating Patients With Abnormal Levels of Gastric Acid
NCT00550368	Not specified	COMPLETED	Clinical Experiment of Helicobacter Pylori Transmission
NCT01399164	Not specified	COMPLETED	Cobalamin Absorption From Fortified Food

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ESOMEPRAZOLE	4	3
OMEPRAZOLE	4	1